Showing: 1 - 2 of 2 RESULTS

How Can Pharma Companies Simplify the Five-Phase Drug Development Process? Infiniti’s Experts Highlight the Need for Product Research Solutions

The increasing competition of the pharmaceutical industry has encouraged companies to invest in innovation and drug development. However, the drug development process is challenging, and without appropriate guidance, developers can face various roadblocks. What is the solution? Infiniti’s product research solutions enable companies to identify, evaluate, and strategize for potential roadblocks through the process. Additionally, our product research experts provide drug developers with crucial insights regarding target customers, regulatory requirements, and competitors’ strategies through the process. This further provides companies with a strategic advantage and enables them to successfully develop and launch a new drug and monitor their success efficiently. To leverage Infiniti’s product research solutions for comprehensive insights regarding the drug development process and an effective strategy, request a free proposal.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201008005908/en/

Five Phases of the Drug Development Process (Graphic: Business Wire)

With constant technological and pharmaceutical advancements, the pharmaceutical industry is continually becoming more competitive and challenging. Pharmaceutical companies need to focus on innovation and stay ahead of the curve to acquire and maintain market share successfully. Therefore, many pharma companies and researchers have shifted focus on drug development. The drug development process is long drawn and includes multiple phases. It is a five-phase process in the United States and acquiring regulatory approval from the Food and Drug Administration (FDA) is extremely challenging. Therefore, Infiniti’s experts decided to simplify the five-phase drug development process and discuss the value of product research solutions during every stage of the process in their recent article.

Gain comprehensive insights into the five phases of the drug development process and the value of product research solutions by reading the complete article here.

“Although the drug development process becomes easier with more available resources, workforce, and a better understanding of the regulatory requirements, many major pharma companies may still struggle to complete the process without experts’ guidance,” says a pharmaceutical industry expert at Infiniti Research.

Infiniti’s product research experts discussed the following five phases of the drug development process:

  • Discovery and development of a particular compound that elicits a desirable effect on the druggable target for any disease and developing a drug candidate

  • Preclinical research involves testing of the drug candidate on an animal species with similar genetic makeup as humans and gaining an understanding of the dosage and toxicity levels

  • Designing a clinical trial, developing a protocol, and submitting an IND application is part of the third phase of the drug development process

  • The relevant information procured from the preclinical and clinical research is submitted to the FDA for review, and it is either approved, delayed, or referred to an advisory committee for further review

  • The fifth phase involves surveillance of the drug after it has been approved, manufactured, and marketed. This aims to analyze the long-term efficacy and safety of the drug and involves various inspections by FDA representatives

To learn how Infiniti Research helps pharma companies strategize for each phase efficiently, and overcome potential bottlenecks with product research

What’s Challenging Growth in the Healthcare M&A Space During the COVID-19 Crisis? Infiniti’s M&A Support Experts Discuss the Future

The COVID-19 pandemic has caused economic disruption in many major segments of North America, Europe, and APAC regions. For healthcare M&A this has translated into the collapse of deals that were underway and limited options for companies in the healthcare M&A space. How can healthcare M&A recover from the business implications of the COVID-19 pandemic? Infiniti’s experts observed that the high dependency on healthcare is expected to cause a surge in valuations once the situation normalizes. With Infiniti’s M&A support solutions, healthcare companies can focus on finding the ideal deal shortly and gain data-driven guidance from our experts. To stay a step ahead of changing market dynamics, and tackle the impact of the COVID-19 crisis on healthcare M&A, request a free proposal.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201001005753/en/

Three Major Challenges Impacting the Healthcare M&A Space During the COVID-19 Crisis (Graphic: Business Wire)

The global healthcare sector has witnessed challenging times due to the COVID-19 pandemic in recent times. Healthcare institutions, medical professionals, and healthcare company boards are attempting to cope with the pandemic’s startling changes. The healthcare M&A space was similarly impacted, and healthcare mergers have reduced substantially in the second quarter of 2020. As the world works towards recovery, healthcare companies need to understand the impact of the COVID-19 crisis on healthcare M&A and accordingly prepare for the future. Therefore, in their recent article, Infiniti’s M&A support experts discuss the biggest challenges of COVID-19 in the healthcare space, and two minor factors positively impacting the recovering healthcare M&A space.

“While investor support has increased due to the increasing need for healthcare globally, social and political unrest, struggling economies and volatility in financial markets are testing the healthcare industry. Healthcare M&A may be one of the most effective solutions to this crisis,” says an M&A support expert at Infiniti Research.

Speak to our industry experts to gain data-driven insights on the implications of COVID-19 in the healthcare industry, and strategize for the post-COVID era.

Infiniti’s experts identified the following three major challenges caused by the COVID-19 pandemic in healthcare M&A:

  • Nationwide lockdowns and limitations for governing bodies have led to delays in acquiring regulatory clearance.

  • The impact of COVID-19 on healthcare M&A participants will change the valuation of both the buyer and seller.

  • Due to renewed safety and hygiene protocols, and social distancing has made it challenging for companies to conduct thorough due diligence, and delayed third-party approvals.

Gain comprehensive insights into the impact and solutions of these major challenges by reading the complete article here.

About Infiniti Research

Established in 2003, Infiniti Research is a leading market intelligence company providing smart solutions to address your business challenges. Infiniti Research studies markets in more than 100 countries to analyze competitive activity, see beyond market disruptions and develop intelligent business strategies. To know more, visit: https://www.infinitiresearch.com/about-us

View source version on businesswire.com: https://www.businesswire.com/news/home/20201001005753/en/

Contacts

Infiniti Research
Anirban Choudhury
Marketing Manager
US: +1 844 778 0600
UK: +44 203 893 3400
https://www.infinitiresearch.com/contact-us

Source